Thursday 7 May, 2026
Introduction: Preclinical efficacy models that recapitulate Leishmania parasite infection and treatment response can play a key role in developing much-needed…
Read moreAbstracts
PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING OF ANTIDEPRESSANTS: A SCOPING REVIEW OF EXISTING MODELS, APPLICATIONS, AND SOFTWARE TOOLS
Thursday 7 May, 2026
Introduction and Objectives: Major depressive disorder affects an estimated 5.7% of the global adult population and represents a substantial contributor…
Read morePREDICTING PROGRESSION-FREE SURVIVAL FOR ABSK-011 (IRPAGRATINIB) IN ADVANCED FGF19+ HCC PATIENTS VIA JOINT MODELING OF TUMOR GROWTH DYNAMICS
Thursday 7 May, 2026
Objectives: FGF19 overexpression (+) occurs in ~30% of hepatocellular carcinoma (HCC) cases and is associated with poor prognosis. The FGF19/FGFR4…
Read morePRECLINICAL-TO-CLINICAL PREDICTIONS OF PHASE 2B CLINICAL TRIAL EFFICACY IN TUBERCULOSIS THROUGH BACK-TRANSLATIONAL MODELING OF RIFAPENTINE-CONTAINING REGIMENS
Thursday 7 May, 2026
Objectives: Tuberculosis (TB) remains the leading cause of infectious disease mortality worldwide [1]. The development of improved and shorter treatment…
Read moreJOINT MODELING OF TUMOR SIZE AND PROGRESSION-FREE SURVIVAL (PFS) TO SUPPORT PHASE 3 DOSE SELECTION OF ODRONEXTAMAB PLUS CHEMOTHERAPY IN PATIENTS WITH UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Thursday 7 May, 2026
Introduction: In first‑line (1L) DLBCL, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (R‑CHOP) remains a common treatment. However, up to…
Read moreEvaluation of the Impact of Machine-learning-informed Optimal Study Design on the Identifiability of Key Pharmacokinetic Parameters in Preclinical Intravenous Rat Pharmacokinetic Studies
Thursday 7 May, 2026
Introduction: Preclinical pharmacokinetic (PK) studies for new drug candidates are typically designed empirically and in a compound agnostic manner. Optimal experimental…
Read moreOpen source software from the Uppsala University Pharmacometrics group
Thursday 7 May, 2026
The Uppsala University pharmacometrics group develops and maintains several different open-source software packages. ncappc – Performs traditional non-compartmental analysis (NCA)…
Read morePBPK/PD MODELING TO ASSESS ANTIBODY-INDUCED IMMUNE CELL DEPLETION AND PD-DEPENDENT CLEARANCE IN SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS
Thursday 7 May, 2026
Introduction: Physiologically based pharmacokinetic (PBPK) modeling has become an essential tool in modern drug development, enabling a mechanistic characterization of…
Read moreDEVELOPMENT OF A GENERAL PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL OF DRUG DISTRIBUTION AFTER PERIOCULAR ADMINISTRATION
Thursday 7 May, 2026
Introduction: Periocular injections represent an alternative route for ocular drug delivery, offering potential advantages in terms of efficacy, safety, and…
Read moreQuantitative Systems Pharmacology Modeling to Explore Alternative Step-Up Dosing Regimens for Tarlatamab, a DLL3-Targeting T-Cell Engager
Thursday 7 May, 2026
Objectives: Tarlatamab is a DLL3/CD3 bispecific T-cell engager (TCE) recently approved by the FDA for the treatment of extensive-stage small…
Read more